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Abstract 
 
Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related 
disorders. These drugs are well tolerated in the short term, but long-term treatment was 
associated with adverse events in observational studies. We aimed to confirm these 
findings in an adequately powered randomized trial. 
 
Methods: We performed a 3x2 partial factorial double-blind trial of 17,598 participants 
with stable cardiovascular disease and peripheral artery disease randomly assigned to 
groups given pantoprazole (40 mg daily, n=8791) or placebo (n=8807). Participants were 
also randomly assigned to groups that received rivaroxaban (2.5 mg twice daily) with 
aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg) alone. 
We collected data on development of pneumonia, Clostridium difficile infection, other 
enteric infections, fractures, gastric atrophy, chronic kidney disease, diabetes, chronic 
obstructive lung disease, dementia, cardiovascular disease, cancer, hospitalizations, and 
all-cause mortality every 6 months. Patients were followed up for a median of 3.01 years, 
with 53,152 patient years of follow up.   
 
Results: There was no statistically significant difference between the pantoprazole and 
placebo groups in safety events except for enteric infe tions (1.4% vs 1.0% in the placebo 
group; odds ratio, 1.33; 95% CI, 1.01–1.75). For all other safety outcomes, proportions 
were similar between groups except for C difficile infection, which was approximately 
twice as common in the pantoprazole vs the placebo group, although there were only 13 
events, so this difference was not statistically signif cant. 
 
Conclusions: In a large placebo-controlled randomized trial, we found that pantoprazole 
is not associated with any adverse event when used for 3 years, with the possible 
exception of an increased risk of enteric infections. Clinicaltrials.gov identifier: 
NCT01776424 (https://clinicaltrials.gov/ct2/show/NCT01776424) 
 
KEY WORDS:  reflux, thrombosis, CVD, bacteria 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6 
Introduction 
 
Proton pump inhibitors (PPI) are one of the most widely used classes of drugs in the 
United States (1).    PPIs are the most effective drugs for treating gastro-esophageal 
reflux disease (GERD) (2).  Given their profound impact in reducing acid secretion 
(3), PPIs are recommended in many other acid related conditions such as the 
management of dyspepsia (4), as part of Helicobacter pylori eradication therapy (5) 
and for prevention of peptic ulcer bleeding in high risk patients on aspirin and/or 
non-steroidal anti-inflammatory drugs.  Recent randomized controlled trial data 
also suggests that high dose PPI therapy may reduce high-grade dysplasia and 
esophageal adenocarcinoma in patients with Barrett’s esophagus (6).  Acid secretion 
returns towards normal within 12-24 hours of discontinuation of therapy, so PPIs 
are often used long term, particularly in patients with GERD symptoms (2).   Acid 
related conditions such as dyspepsia and GERD occur in over 25% of the population 
(7, 8) and, given that most patients take PPI therapy long term, it is not surprising 
that the US spends over $5 billion annually on these drugs (9).  Omeprazole was the 
first PPI to be developed and this is on the World Health Organization list of 
essential medications (10).  
 
Given how commonly acid suppressive medications are used, it is important to 
ensure that this class of drugs is safe.  However, concerns have been raised 
regarding potential harms of long-term PPI therapy.  Observational studies have 
suggested an association between PPI therapy and risk of pneumonia (11), fracture 
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(12), enteric infection (13), Clostridium difficile (C. difficile) associated diarrhea (14), 
cerebrovascular events (15), chronic renal failure (16), dementia (17) and all-cause 
mortality (18).  These papers are often reported in the media with sensational 
headlines that can alarm patients taking PPI therapy.  There are balancing articles 
that more carefully discuss the risks and benefits of taking PPI therapy (19) but 
these receive less media attention.  These associations may relate to confounding as 
patients receiving PPI may be inherently sicker and statistical adjustments in 
observational analyses cannot rectify for differences in known and unknown 
confounders (20).  There is equipoise between concerns regarding the long-term 
safety of PPI therapy versus their efficacy in treating acid related diseases.  We have 
previously reported that rivaroxaban 2.5mg twice daily with aspirin daily reduced 
cardiovascular outcomes in patients with stable cardiovascular disease (21).  In this 
trial, we also evaluated whether the PPI pantoprazole is more effective than placebo 
in preventing upper GI events in patients receiving aspirin and/or rivaroxaban and 
we also prospectively evaluated the safety of PPIs in this setting. 
 
Methods 
 
Trial Design 
The Cardiovascular Outcomes for People Using Anticoagulant Strategies (COMPASS) 
trial is a 3-by-2 partial factorial, multicenter, double-blind, randomized placebo-
controlled trial, evaluating patients with stable atherosclerotic vascular disease.  
The detailed study design has been published (22).  Participants were randomized 
to rivaroxaban 2.5 mg twice daily with aspirin 100mg once daily, rivaroxaban 5mg 
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twice daily alone or aspirin 100mg once daily alone to compare the primary 
outcome of cardiovascular death, stroke or myocardial infarction in these three 
arms.  All participants who were not already taking a PPI at baseline (64%) were 
randomized to receive either pantoprazole 40mg or matching placebo once daily.  
We use the term participants, rather than patients, as not all of those taking part in 
this research would have been patients throughout the trial but all participated in 
the randomized controlled trial.  The rivaroxaban part of the trial was stopped early 
for evidence of reduction in major vascular events from the combination of 
rivaroxaban and aspirin compared with aspirin alone (21). The pantoprazole part of 
the trial was continued as planned for three years (22) and the protocol is available 
in the Supplementary Appendix.  Participants in the PPI arm were recruited from 
580 centers in 33 countries and the trial was conducted according to Good Clinical 
Practice.  All relevant authorities and research ethics boards approved the trial.  
Written informed consent was obtained from all participants. All authors had access 
to the study data and reviewed and approved the final manuscript.  Bayer AG 
sponsored the trial; all data were analyzed independently at the Population Health 
Research Institute and the first author acts as a guarantor for the veracity of the 
data and analyses.     
 
Randomization, concealment of allocation and blinding 
All participants were randomly assigned to receive low-dose rivaroxaban with 
aspirin, rivaroxaban alone, or aspirin alone stratified by center and use of PPI. 
Eligible participants were further randomized 1:1 to receive pantoprazole (40 mg 
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once daily) or matched placebo stratified by center.  The randomization schedules 
were computer-generated and delivered through an interactive web response 
system.  All active interventions and placebo were identical in appearance and taste.  
Participants, health care staff and researchers were blinded to treatment allocation.   
 
Trial population, intervention and follow up 
Participants were eligible if they had stable coronary or peripheral arterial disease 
and were aged 65 years or older.  Younger atherosclerotic participants were eligible 
if they had arterial disease involving two cardiovascular beds and/or had two 
additional risk factors (see Supplementary Appendix).  Patients were randomized to 
receive pantoprazole 40mg once daily or placebo except if they had a clinical need 
for long term PPI therapy or were unwilling to discontinue their H2 receptor 
antagonist or PPI therapy.  If participants were otherwise eligible for the 
cardiovascular component of the trial (21, 22), they continued in the study and all 
outcomes were measured.  Participants were excluded if they had a high risk of 
bleeding from any site, had severe heart failure, significant renal impairment, need 
for dual antiplatelet therapy or known hypersensitivity to any of the study drugs.  
Further details of exclusion criteria are given in the Supplementary Appendix.  
Following randomization participants were seen at one month, 6 months and then 
at 6-month intervals for three years.  Adherence to study medication was assessed 
by return tablet count at each visit with >80% of medication taken being defined as 
compliant.  We defined discontinuation as any patient that permanently 
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discontinued pantoprazole or placebo at any point in the trial and for the remainder 
of the trial. 
 
Outcomes 
The rates of cardiovascular disease events (e.g. myocardial infarction, stroke, 
cardiovascular death, coronary heart disease acute limb ischemia) as defined by the 
primary and secondary efficacy outcomes for the rivaroxaban and/or aspirin arms 
of the trial (22) were compared between the pantoprazole and placebo arms.  We 
defined safety outcomes of special interest based on previous reports of possible 
harms of PPI therapy (11-18) including pneumonia, Clostridium difficile infection, 
other enteric infections, fracture, gastric atrophy, chronic kidney disease, and 
dementia.  We also evaluated diabetes mellitus and chronic obstructive lung disease 
as previous observational data had suggested increased rates of these diseases in 
patients taking PPI therapy although this was not the primary focus of the analyses 
(23).  In addition, hospitalization rates for both cardiovascular and non-
cardiovascular events were evaluated in the pantoprazole and placebo groups.  
Participants were interviewed every 6 months and questioned whether they had a 
new onset of any of these events with questions on the case record form so that each 
participant was asked about each adverse event and medical records were reviewed 
as appropriate.  Cardiovascular events were independently adjudicated but all the 
other events were taken from the interview without adjudication. 
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Sample size calculations and statistical analyses 
Sample size calculations for the trial were not calculated based on safety outcome 
assumptions.  Retrospective calculations based on observed proportions of the 
safety outcomes in the trial varied depending on the frequency of adverse events 
seen in the study.  Excluding C. difficile where event rate was very small the smallest 
effect size that could be detected related to pneumonia with an OR of 1.27 and the 
largest related to dementia with an OR of 2.06.  Power calculation results are 
provided in more detail in Supplementary Table 1.  All these calculations assumed 
the proportions seen in the placebo group with 80% power and 5% type 1 error. 
 
 
All events occurring in the randomized participants are included in the intention to 
treat (ITT) analysis utilizing the time to the first occurrence of the cardiovascular 
events, mortality, cancer and hospitalizations for pantoprazole versus placebo from 
the time of randomization until the date of formal trial termination. Differences in 
rates between pantoprazole 40 mg o.d vs. pantoprazole placebo were evaluated 
using a log-rank test stratified by antithrombotic study treatment (three strata 
levels: rivaroxaban 2.5 mg b.i.d + aspirin 100 mg o.d; rivaroxaban 5 mg b.i.d + 
aspirin placebo; rivaroxaban placebo + aspirin 100 mg o.d), conducted at a two-
sided 5% type I error level.  Kaplan-Meier estimates of cumulative risk were used to 
evaluate the timing of event occurrence in the pantoprazole and placebo study 
groups. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained from 
stratified Cox proportional-hazards models and all reported P values are two-sided.   
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For all other safety events, the number of participants who experienced an outcome 
in the pantoprazole versus placebo group were summarized and the odds ratio (OR) 
was calculated using logistic regression and two-sided 5% type I error.  The 
summary measure for these events was OR rather than HR as the precise time point 
of the event was not captured but simply whether or not a predefined adverse event 
had occurred at each 6-month time point.  No adjustment was made for multiple 
testing.  Safety outcomes were evaluated using an intention-to-treat principle and a 
sensitivity analysis of the safety outcomes was also conducted excluding those who 
permanently discontinued pantoprazole or placebo therapy during the trial.  
Number needed to harm was calculated using the Newcombe Wilson method (24). 
 
Analyses were conducted using SAS software, version 9.4 of the SAS System for 
SunOS (SAS Institute Inc, Cary, NC, USA). 
 
Results 
17,598 participants were recruited between March 2013 and May 2016 and 
randomized to pantoprazole 40mg or placebo.  The main reason for exclusion from 
the PPI part of the trial was that patients were considered to have a clinical need for 
PPI (based on their physicians’ judgment) at the time of randomization (Figure 1).  
Those that were excluded from the trial because of continuing need for PPI were 
similar in all baseline characteristics to those that were enrolled into the PPI 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
randomized trial apart from a higher proportion had a past medical history of peptic 
ulcer disease (Supplementary Table 2).   
 
Baseline characteristics are summarized in Table 1.   8,791 participants were 
randomized to pantoprazole 40mg once daily and 8,807 were randomized to 
placebo. The mean age of participants was 67.6 years, 13792 (78%) were male, 
4074 (23%) were current smokers, 872 (5%) were taking non-steroidal anti-
inflammatory drugs and 2.6% had a past history of peptic ulcer disease.   One 
hundred and thirty-five (0.8%) participants were taking PPI at the start of the trial 
and randomized to pantoprazole or placebo (Table 1). The median follow-up was 
3.01 years (inter-quartile range (IQR) = (2.49 to 3.59), range 2 days to five years one 
month) thus accruing 53,152 patient-years of follow up, 1,884 participants (21%) in 
the pantoprazole group and 1,975 (22%) in the placebo group permanently 
discontinued the medication.  The median time to permanent discontinuation was 
338 days (IQR = (109 to 679)) and the reasons are described in Supplementary 
Table 3.  In those that continued their medication, 295 participants (3.63%) in the 
PPI group took their medication for <80% of the time compared with 288 (3.53%) 
in the placebo group. 
 
Cardiovascular and mortality safety outcomes 
There was no significant difference in the primary efficacy outcome of the 
rivaroxaban/aspirin trial (21) for the composite outcome of myocardial infarction, 
stroke or cardiovascular death (HR = 1.04; 95% CI = 0.93 to 1.15) (Table 2, Figure 2) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
with pantoprazole compared to placebo.  There was no statistically significant 
difference in the secondary cardiovascular efficacy outcomes of the 
rivaroxaban/aspirin trial (22) and no difference between pantoprazole and placebo 
when myocardial infarction (HR = 0.94; 95% CI = 0.79 to 1.12), stroke (HR = 1.16; 
95% CI = 0.94 to 1.44), and acute limb ischemia (HR = 1.13; 95% CI = 0.73 to 1.75) 
were considered separately (Table 2, Figure 3).  Hospitalization rates (HR = 1.04; 
95% CI = 0.99 to 1.09) and all-cause mortality (HR = 1.03; 95% CI = 0.92 to 1.15) 
were also similar in the pantoprazole and placebo arms (Table 2).   
 
 
Other pre-specified safety outcomes 
There were 864 new cancer diagnoses during follow up in participants randomized 
to pantoprazole or placebo.  One hundred and sixty-nine cancers were from the 
gastrointestinal tract with 86 in the pantoprazole and 83 in the placebo group 
(Table 2). There was no statistically significant difference in overall cancer rates (HR 
= 0.99; 95% CI = 0.87 to 1.13) or in any of the primary sites of cancer between the 
two groups (Table 2).   There was no statistically significant difference between 
pantoprazole and placebo in the proportion of participants who experienced pre-
specified non-cardiovascular events of interest that are associated with PPI use in 
observational studies (8) (Table 3), including pneumonia, fracture, new diagnosis of 
diabetes mellitus, chronic kidney disease, dementia, chronic obstructive lung 
disease, gastric atrophy. However, enteric infections were more frequent in the 
pantoprazole group (OR = 1.33; 95% CI = 1.01 to 1.75) (Table 3).  The number 
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needed to harm for enteric infections was 301 (95% CI 152 to 9,190) after a median 
of three years of PPI use.  Results were similar when participants who permanently 
discontinued pantoprazole or placebo were excluded from the analysis (Table 4).  
There were 134 (0.8%) participants that were on PPI before the start of the trial.  
They may have been self-selected to be tolerant of PPI so this group were removed 
in a sensitivity analysis and this gave similar results (Supplementary Table 4).  
Patients with dementia, severe COPD and glomerular filtration rate (GFR) of 
15ml/min were excluded from participating in the trial.  Diabetes mellitus was not 
excluded and those that already have the disease cannot develop new onset diabetes 
so the denominator is falsely increased in the baseline analysis.  Excluding this 
group did not change the estimate of effect of PPI versus placebo (OR = 1.15; 95% CI 
= 0.89 to 1.50, p=0.28).  Excluding those with a GFR <30ml/min at baseline did also 
not impact on the risk of chronic renal disease (OR = 1.20; 95% CI = 0.96 to 1.51 
p=0.11). 
 
Discussion 
 
To our knowledge, this is the largest PPI trial for any indication and the first 
prospective randomized trial to evaluate the many long-term safety concerns 
related to PPI therapy.  It is reassuring that there was no evidence for harm for most 
of these events other than an excess of enteric infections.  This is in contrast to 
systematic reviews of observational studies that report the association of PPI 
therapy with harms such as pneumonia (26), fracture (26) and cerebrovascular 
events (27).  Biologically plausible mechanisms have been advanced to suggest 
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these associations are causal such as a PPIs causing a change in the upper 
gastrointestinal tract microbiome leading to pneumonia if aspirated (28), inhibition 
of calcium absorption leading to increased risk of fracture (29) and cardiovascular 
events may relate to PPIs reducing the activity of nitric oxide synthase (30).   
 
A well-known maxim of epidemiology is that association is not causation (31) and 
these data suggest that most of these associations relate to residual confounding or 
biases that are inherent in observational studies (9).  A significant proportion of 
patients are prescribed PPI therapy inappropriately (32) and in these cases, it is 
reasonable to advocate strategies to discontinue acid suppression (33).  However, 
when there is a clinical need for PPI therapy (3-6) these data suggest that the 
benefits are likely to outweigh any putative risks.   
 
We found a statistically significant increased risk of enteric infections in those 
allocated to PPI, although the risk is lower than estimated by systematic reviews of 
observational studies (13).  The data in the current randomized trial were not 
adjusted for multiple testing so this result should be interpreted with caution.  The 
risk of PPI therapy and enteric infection, however, has biologic plausibility as acid 
secretion protects against ingestion of organisms causing enteric infection.  This is 
the only association where past observational studies were conducted to specifically 
test this hypothesis (34) rather than analyses of administrative databases or re-
analyses of large cohort studies testing other primary hypotheses.  The number 
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needed to harm in this analysis is over 300 with three years of PPI use so the 
benefits are likely to outweigh the harms even for this adverse event. 
 
There are some potential limitations of this trial. Despite the fact that our study is by 
far the largest placebo-controlled trial evaluating a PPI, the number of events for 
some of the adverse outcomes are small.  This issue is exemplified by the outcomes 
Clostridium difficile and gastric atrophy, where the number of events were modest 
even in this large trial.  The incidence of gastric atrophy is likely to be 
underestimated in this trial as it relies on participants being referred for endoscopy 
and having gastric biopsy and this is not mandated for all participants.  It is 
somewhat reassuring that the proportion of gastric atrophy cases were similar 
between the two groups but as the number of participants with gastric atrophy was 
small this may have biased the results towards the null.  Gastric atrophy is a risk 
factor for B12 deficiency and gastric cancer.  These adverse events have also been 
associated with PPI therapy (35) and so these associations are not supported by 
these randomized data although a small effect cannot be excluded.  There was an 
apparent excess of C. difficile associated diarrhea observed in our trial but given the 
low numbers this needs to be interpreted cautiously.  Even if the excess of these 
events is real, the rarity of these events with over 53,000 patient years of follow up 
suggests that any potential adverse effect will be low in terms of absolute excess of 
these events.   We separated C. difficile associated diarrhea from other enteric 
infections as the former is caused in the community primarily by disruption of 
existing gut microbiota by antibiotics or diseases such as ulcerative colitis whereas 
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the latter is transmitted by ingestion of infected food or drink.  Previous studies 
have also taken the approach of evaluating C. difficile associated diarrhea and other 
enteric infections separately (13).   These adverse events were mainly obtained by 
patient interview every six months.  Although participants were specifically asked 
about these events it is possible that there was some misclassification.  As this was a 
double-blind randomized trial misclassification will have been similar in both arms, 
but this may have biased results towards the null.  Previous studies that have 
reported an association between PPI and adverse event (11, 12, 14, 17, 18) have 
usually relied on administrative databases, which are likely to be at least as 
inaccurate as direct participant interview, so this is unlikely to be the explanation 
for our negative findings.   
 
Furthermore, cardiovascular outcomes were independently adjudicated and as this 
trial was conducted in cardiovascular centers, it is highly unlikely that significant 
misclassification occurred.  Cardiovascular outcomes showed very similar results to 
other outcomes in this trial again supporting the belief that misclassification is 
unlikely to explain the lack of association between PPI and most of the harms 
evaluated.  However, as other outcomes relied on researcher interview with the 
participant every 6 months it is possible that there was some non-differential 
misclassification for these outcomes that can bias results towards the null. 
 
It is always possible that PPIs are associated with a more modest risk of long-term 
adverse effects than currently suggested by observational studies.  Such a possibility 
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can never be excluded no matter how large the sample size of the trial.  It is 
reassuring, however, that the hazard ratios and odds ratios reported in this trial are 
lower than the lower end of the 95% CI of the observational data for pneumonia 
(23), fracture (26), cardiovascular disease (27), chronic renal disease (16), 
dementia (17) and all-cause mortality (18).  Some data suggest adverse events 
associated with PPI therapy are not seen until after five years of therapy (36) and 
this trial had a mean follow up of three years and a maximum follow up of 5 years 
that was achieved in only a small proportion of patients. However, all adverse 
events have studies that report observing an excess of events after one year of PPI 
therapy (17, 18, 23, 26, 27, 37) and almost all patients in the COMPASS trial 
exceeded this time frame.  There is also no evidence of time effects seen in the 
cumulative incidence of risk of cardiovascular events with PPI therapy compared 
with placebo. 
 
In conclusion, these data suggest PPI therapy is safe for up to a median of three 
years.  As with all drugs, PPI therapy should only be used when the benefits are 
expected to outweigh the risks and should be used according to recommended dose 
and duration of treatment (38).  However, this trial suggests that limiting 
prescription of PPI therapy because of concerns of long-term harm is not 
appropriate.   
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Figure 1.  Consort diagram 
 
 
Figure 2.  Cumulative incidence of combined cardiovascular death, myocardial 
infarction and stroke in the pantoprazole versus placebo arm  
 
 
Figure 3.  Cumulative incidence of individual cardiovascular events in the 
pantoprazole versus placebo arm  
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Table 1.  Baseline characteristics of participants       
 
Characteristic Pantoprazole 
(N = 8791) 
Placebo 
(N = 8807) 
Age (years) 67.6 ± 8.1 67.7 ± 8.1 
Female sex- no. (%) 1937 (22) 1869 (21) 
Race – no. (%) 
White European 
Asian 
Black/African-American 
Latin American 
 
5265 (60) 
1363 (15.5) 
97 (1) 
2066 (23.5) 
 
5267 (60) 
1384 (16) 
108 (1) 
2048 (23) 
Geographic region – no. (%) 
North America 
South America 
Western Europe 
Eastern Europe 
Asia Pacific and other 
 
 
1241 (14) 
2209 (25) 
2187 (25) 
1890 (21.5) 
1264 (14) 
 
1243 (14) 
2194 (25) 
2207 (25) 
1895 (21.5) 
1268 (14) 
Body mass index 28.3 ± 4.7 28.4 ± 4.7 
Smoking status – no. (%) 
Current  
Former 
 
2064 (23.5) 
3764 (43) 
 
2010 (23) 
3808 (43) 
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Never 2693 (34) 2989 (34) 
Previous MI – no. (%) 5403 (61.5) 5404 (61) 
Previous stroke – no. (%) 350 (4) 366 (4) 
Previous cancer – no. (%) 450 (5) 491 (6) 
Previous peptic ulcer – no. (%) 228 (3) 222 (2.5) 
Inflammatory bowel disease – 
no (%) 
37 (0.4) 56 (0.6) 
Diverticulitis - no. (%) 131 (1.5) 120 (1.4) 
Liver disease – no. (%) 85 (1) 83 (1) 
Diabetes – no. (%) 3363 (38) 3369 (38) 
Heart failure – no. (%) 2181 (25) 2138 (24) 
Estimated GFR – no. (%) 
<30 ml/min 
30 to <60 ml/min 
≥ 60 ml/min 
 
 
75 (0.9) 
1878 (21) 
6838 (78) 
 
77 (0.9) 
1917 (22) 
6810 (77) 
Medication – no. (%) 
Taking PPI at start of trial 
NSAIDs  
SSRIs  
Hypoglycemic agents 
ACE inhibitor/ARBs 
 
56 (0.6) 
425 (5) 
257 (3) 
2785 (32) 
6269 (71) 
 
78 (0.9) 
447 (5) 
258 (3) 
2784 (32) 
6286 (71) 
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Beta blockers 
Calcium channel blockers 
Lipid lowering agents 
Diuretics 
6137 (70) 
2237 (25) 
7775 (88) 
2572 (29) 
6122 (70) 
2265 (26) 
7823 (89) 
2522 (29) 
 
NSAID = non-steroidal anti-inflammatory drug 
SSRI = selective serotonin re-uptake inhibitor 
ACE = angiotensin converting enzyme 
ARB = angiotensin receptor blockers  
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Table 2.  Cardiovascular events, cancers and hospitalizations. 
 
Outcome Pantoprazole 40mg od 
(N=8791) 
Placebo 
(N= 8807) 
Pantoprazole versus 
placebo 
 No. of first 
events (%) 
Annual rate 
(%/yr) 
No. of first 
events (%) 
Annual 
rate 
(%/yr) 
Hazard ratio  
(95% CI) 
P value 
Primary efficacy 
outcome 
      
MI, stroke or 
cardiovascular death 
691 (7.9) 2.66 668 (7.6)  2.57 1.04 (0.93 to 1.15) 0.51 
Secondary efficacy 
outcomes 
      
MI, ischemic stroke, 
CHD death or ALI 
588 (6.7) 2.27 572 (6.5)  2.20 1.03 (0.92 to 1.16) 0.61 
MI, ischemic stroke, 
cardiovascular death 
or ALI 
707 (8.0)  
2.72 
683 (7.8)  2.63 1.04 (0.94 to 1.15) 0.50 
Death 
All cause 
Cardiovascular 
Non-cardiovascular 
CHD 
 
630 (7.2) 
343 (3.9) 
287(3.3) 
194 (2.2) 
 
  
2.37  
1.29  
1.08  
0.73 
 
614 (7.0) 
333 (3.8) 
281 (3.2) 
200(2.3) 
  
2.31 
1.25 
1.06 
0.75 
 
1.03 (0.92 to 1.15) 
1.03 (0.89 to 1.20) 
1.02 (0.87 to 1.21) 
0.97 (0.80 to 1.18) 
 
0.63 
0.69 
0.78 
0.94 
Individual efficacy 
outcomes 
      
MI 252 (2.9)  0.96 267 (3.0)  1.02 0.94 (0.79 to 1.12) 0.51 
Stroke 184 (2.1)  0.70 159 (1.8)  0.60 1.16 (0.94 to 1.44) 0.16 
ALI 43 (0.5)  0.16 38 (0.4)  0.14 1.13 (0.73 to 1.75) 0.58 
Venous 
thromboembolism 
53 (0.6)  0.20 52 (0.6)  0.20 1.01 (0.69 to 1.49) 0.95 
Cancer 
All new cancers 
GI  
Lung 
Prostate 
Skin 
Breast 
 
 
429 (4.9) 
86 (1.0) 
73 (0.8) 
65 (0.7) 
73 (0.8) 
9 (0.1) 
 
1.65  
0.33  
0.28  
0.25  
0.28  
0.034 
 
435 (4.9) 
83 (0.9) 
77 (0.9) 
73 (0.8) 
70 (0.8) 
18 (0.2) 
  
1.77 
0.31 
0.29 
0.28 
0.26 
0.068 
 
0.99 (0.87 to 1.13) 
1.04 (0.77 to 1.40) 
0.95 (0.69 to 1.31) 
0.89 (0.64 to 1.24) 
1.05 (0.75 to 1.45) 
0.50 (0.22 to 1.11) 
 
0.87 
0.81 
0.75 
0.50 
0.79 
0.08 
 
Hospitalizations 
All 
Cardiovascular 
Non-cardiovascular 
 
 
3074 (35.0) 
1721 (19.6) 
1898 (21.6) 
 
14.51  
7.26  
8.13 
 
3000 (34.1) 
1644 (18.7) 
1901(21.6) 
 
13.96 
6.86 
8.10 
 
1.04 (0.99 to 1.09) 
1.06 (0.99 to 1.13) 
1.00 (0.94 to 1.07) 
 
0.14 
0.10 
0.92 
 
* Defined by the cardiovascular outcomes related to aspirin rivaroxaban arms (10) 
yr = year 
CI = confidence interval 
MI = myocardial infarction 
CAD = Coronary Heart Disease 
ALI = Acute limb ischemia 
GI = gastrointestinal 
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Table 3. Other pre-specified safety outcomes  
Outcomes 
 
Pantoprazole 
40 mg od 
(N=8791) 
 
Placebo 
(N=8807) 
 
Pantoprazole 40mg od versus 
placebo 
no. of incident 
events (%) 
no. of incident 
events (%) 
Odds ratio (95% CI) P value 
Gastric 
atrophy 
19 (0.2) 26 (0.3) 0.73 (0.40 to 1.32) 0.30 
Clostridium 
difficile 
9 (0.1) 4 (<0.1) 2.26 (0.70 to 7.34) 0.18 
Other enteric 
infection 
119 (1.4) 90 (1.0) 1.33(1.01 to 1.75) 0.04 
Chronic kidney 
disease 
184 (2.1) 158 (1.8) 1.17 (0.94 to 1.45) 0.15 
Dementia 55 (0.6) 46 (0.5) 1.20 (0.81 to 1.78) 0.36 
Pneumonia 318 (3.6) 313 (3.6) 1.02 (0.87 to 1.19) 0.82 
Fracture 203 (2.3) 211 (2.4) 0.96 (0.79 to 1.17) 0.71 
COPD 146 (1.7) 124 (1.4) 1.18 (0.93 to 1.51) 0.17 
Diabetes 
mellitus 
513 (5.8) 532 (6.0) 0.96 (0.85 to 1.09) 0.56 
 
CI = confidence interval 
COPD = chronic obstructive pulmonary disease 
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Table 4.  Other prespecified safety outcomes excluding those that permanently 
discontinued pantoprazole or placebo  
Outcomes 
 
Pantoprazole 
40 mg od 
(N=6947) 
 
Placebo 
(N=6868) 
 
Pantoprazole 40mg od versus 
placebo 
no. of incident 
events (%) 
no. of incident 
events (%) 
Odds ratio (95% CI) P value 
Gastric 
atrophy 
10 (0.1) 24 (0.2) 0.71 (0.31 to 1.59) 0.40 
Clostridium 
difficile 
5 (<0.1) 2 (<0.1) 2.48 (0.48 to 12.8) 0.28 
Other enteric 
infection 
60 (0.9) 42 (0.6) 1.42 (0.95 to 2.10) 0.08 
Chronic kidney 
disease 
104 (1.5) 98 (1.4) 1.05 (0.80 to 1.39) 0.73 
Dementia 24 (0.3) 22 (0.3) 1.08 (0.60 to 1.93) 0.80 
Pneumonia 203 (2.9) 185 (2.7) 1.09 (0.89 to 1.33) 0.41 
Fracture 136 (2.0) 150 (2.2) 0.89 (0.71 to 1.13) 0.35 
COPD 94 (1.4) 83 (1.2) 1.12 (0.83 to 1.51) 0.45 
Diabetes 
mellitus 
393 (5.7) 423 (6.2) 0.91 (0.79 to 1.05) 0.21 
 
CI = confidence interval 
COPD = chronic obstructive pulmonary disease 
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What you need to know 
 
 
Evidence before this study 
Observational studies have raised concerns that proton pump inhibitors may be associated with 
increased risk of pneumonia, fracture, clostridium difficile associated diarrhoea, other enteric 
infections, cardiovascular disease, chronic renal disease, dementia and all-cause mortality 
 
New Findings 
Long term adverse events were similar in the pantoprazole compared to the placebo arms of a 
randomized trial with 53,000 patient years of follow up with the possible exception of enteric 
infections which were slightly higher in the pantoprazole group.  
 
Limitations 
Some of the outcomes did not have enough events to exclude a modest increased risk 
 
Impact 
Proton pump inhibitors are not associated with any long-term harm and therefore the benefits 
are likely to outweigh the risks of these medications provided they are used for clinically 
appropriate indications.  
 
 
Lay summary 
 
Concerns have been raised regarding the long-term safety of acid suppressing medications, 
proton pump inhibitors.  17,598 participants were randomized to the proton pump inhibitor 
pantoprazole 40mg daily or placebo and followed up for three years.  There was a slight 
increased risk of enteric infection in patients taking proton pump inhibitors.  There was, 
however, no difference in pneumonia, fracture, clostridium difficile associated diarrhoea, 
cardiovascular disease, chronic renal disease, dementia and all-cause mortality in patients 
taking proton pump inhibitors.   
